Francesco Fiore
About
In The Last Decade
Francesco Fiore
60 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 90
- Hepatology 1.1k
- Oncology 725
- Surgery 637
- Pulmonary and Respiratory Medicine 629
- Epidemiology 526
Countries citing papers authored by Francesco Fiore
This map shows the geographic impact of Francesco Fiore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Fiore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Fiore more than expected).
Fields of papers citing papers by Francesco Fiore
This network shows the impact of papers produced by Francesco Fiore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Fiore. The network helps show where Francesco Fiore may publish in the future.
Co-authorship network of co-authors of Francesco Fiore
This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Fiore. A scholar is included among the top collaborators of Francesco Fiore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Fiore. Francesco Fiore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | 3 | |
| 4 | 8 | |
| 5 | 3 | |
| 6 | 1 | |
| 7 | 88 | |
| 8 | 3 | |
| 9 | 2 | |
| 10 | 1 | |
| 11 | Role of Kras mutations in predicting response and survival in irinotecan-refiractory patients treated with cetuximab and irinotecan for metastatic colorectal cancer: Analysis of 281 patients with individual data | 5 |
| 12 | 18 | |
| 13 | 69 | |
| 14 | SERUM FREE LIGHT CHAINS (SFLC) ASSAY: A SUGGESTIVE NEW CRITERIA FOR EVALUATING DISEASE RESPONSE, PROGRESSION AND RELAPSE IN PLASMA-CELL DISORDERS (PD) AND A PROGNOSTIC FACTOR IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) | 1 |
| 15 | 44 | |
| 16 | 20 | |
| 17 | 13 | |
| 18 | 10 | |
| 19 | 21 | |
| 20 | 28 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.